PURPOSE OF REVIEW: This review summarizes the most recent epidemiological data and advances in research into the pathogenesis, diagnosis and treatment of Clostridium difficile infection (CDI). RECENT FINDINGS: The epidemiology of CDI has changed with the emergence of hypervirulent strains. CDI rates have increased in the community, in children and in patients with inflammatory bowel disease. Although the North American pulsed-field gel electrophoresis type 1, restriction endonuclease analysis group BI, PCR ribotype 027 (NAP1/BI/027) strain remains prevalent in North America, surveillance suggests that it is decreasing in Europe. A similar strain, PCR ribotype 078, is emerging which is associated with community-associated CDI and has been isolated in animals and food products. The Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America have published new guidelines on the epidemiology, diagnosis, treatment, infection control and environmental management of C. difficile. Several novel therapies for CDI are at different stages of development. There have been promising trial results with fidaxomicin, a novel antibiotic for the treatment of CDI and monoclonal antibodies against toxins A and B, which have been shown to significantly reduce CDI recurrence rates. SUMMARY: Major advances have been made in our understanding of the spread and pathogenesis of C. difficile and new treatment options are becoming available.
PURPOSE OF REVIEW: This review summarizes the most recent epidemiological data and advances in research into the pathogenesis, diagnosis and treatment of Clostridium difficile infection (CDI). RECENT FINDINGS: The epidemiology of CDI has changed with the emergence of hypervirulent strains. CDI rates have increased in the community, in children and in patients with inflammatory bowel disease. Although the North American pulsed-field gel electrophoresis type 1, restriction endonuclease analysis group BI, PCR ribotype 027 (NAP1/BI/027) strain remains prevalent in North America, surveillance suggests that it is decreasing in Europe. A similar strain, PCR ribotype 078, is emerging which is associated with community-associated CDI and has been isolated in animals and food products. The Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America have published new guidelines on the epidemiology, diagnosis, treatment, infection control and environmental management of C. difficile. Several novel therapies for CDI are at different stages of development. There have been promising trial results with fidaxomicin, a novel antibiotic for the treatment of CDI and monoclonal antibodies against toxins A and B, which have been shown to significantly reduce CDI recurrence rates. SUMMARY: Major advances have been made in our understanding of the spread and pathogenesis of C. difficile and new treatment options are becoming available.
Authors: A N Ananthakrishnan; R Guzman-Perez; V Gainer; T Cai; S Churchill; I Kohane; R M Plenge; S Murphy Journal: Aliment Pharmacol Ther Date: 2012-02-23 Impact factor: 8.171
Authors: Anca Trifan; Irina Girleanu; Camelia Cojocariu; Catalin Sfarti; Ana Maria Singeap; Carmen Dorobat; Lucia Grigore; Carol Stanciu Journal: World J Gastroenterol Date: 2013-11-14 Impact factor: 5.742
Authors: S E Manzoor; H E Tanner; C L Marriott; J S Brazier; K J Hardy; S Platt; P M Hawkey Journal: J Clin Microbiol Date: 2011-08-17 Impact factor: 5.948